Beta-lactam & Beta-lactamase Inhibitors Market

Market Definition

At an estimated value of over 27.49 billion USD in 2019, the global Beta-lactam and Beta-lactamase market is predicted to thrive at a CAGR of 1.9% and valued at over USD 34.20 billion over the forecast year 2020-2030.

Beta-lactam inhibitors fall under a class of antibiotics that consists of all antibiotic agents that have a beta lactam ring embedded in their molecular structure. These antibiotic agents helps fight against bacterial infections and protozoa infections. The antibiotic agent either completely kills the bacteria or prevents it from growing and expanding. Names of some beta-lactam antibiotics are penicillin, cephalosporin and many others. On the other hand, beta-lactamase inhibitors are a class of drugs that block the activity of beta-lactamase enzymes and restricts the degradation of beta-lactam. Beta-lactamase enzymes are created either constitutively or on exposure to antimicrobials.

Market Dynamics and Trends

The widespread presence of infectious diseases along with the growth in consumption of identical drugs in developing countries indicate the growth of beta-lactam and beta-lactamase inhibitors market. Recent improvements in the healthcare sector and advancement of medical technology have further contributed to this market growth. The surge in number of clinical trials of such drugs have further augmented the growth of the market. However, evolution of antibiotic resistance and misuse due to over the counter availability are expected to impede the growth of beta-lactam and beta-lactamase Inhibitors market. Contradictorily, discovery of advanced prospect molecules and novel combination therapies are anticipated to offer significant opportunities to the market players and hence increase their beta-lactam and beta-lactamase inhibitors market share.  

Market Segmentations and Scope of the Study

The global beta-lactam and beta-lactamase inhibitors market share has been segmented on the basis of type, route of administration, patient type, application/indication (disease level) and end user (healthcare setting). On the basis of type, the market is categorized into individual beta-lactum antibiotics and beta-lactum/beta-lactamase inhibitor combination. On the basis of route of administration, the market is segmented into oral administration, parental administration and other routes. On the basis of patient type, the market is segmented into adult patients and pediatric patients. On the basis of application/indication (disease level), the market is segmented into gynecological infections, intrabdominal infections, intraoperative prophylaxis,respiratory infections, skin and soft tissue infections (SSTI), urinary tract infections (UTI), bloodstream infections (BSI) and other infections. On the basis of end user (heathcare setting), the market is segmented into academic institutions, clinics, hospitals and research laboratories.in terms of geography, the market is categorized into North America, Europe, Asia Pacific and RoW.

Geographical Analysis

The North America region is anticipated to hold the major market share as a result of advanced health care facilities and infrastructure in conjunction with rise in acceptance of beta-lactam and beta-lactamase inhibitors.

The Asia Pacific region is predicted to show rapid and consistent growth in market share within the forecast period. This region also indicates increased prevalence of infectious diseases in addition to rise in consumption of such drugs, which also serves as favorable factor for the beta-lactam and beta-lactamase inhibitor market.

Competitive Landscape

Lucrative growth opportunities makes the Beta-lactam and Beta-lactamase inhibitors market extremely competitive. Some of the major players in the market include Alkem Laboratories Ltd., Aurobindo Pharma, Cipla Inc., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin Ltd., Meiji Holdings Co. Ltd., Merck & Co. Inc., Pfizer Inc., Sandoz International GmbH (Novartis), Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Ltd.,Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris (formerly Mylan N.V.), Zeelab Laboratories Ltd., Zentiva Group B.V., Zydus Lifesciences Limited (Cadila Healthcare) and others. A number of developmental strategies have been adopted by companies in the recent years to further promote the growth of the market.

Key Benefits

• The Beta-lactam and Beta-lactamase Inhibitor market report provides the quantitative analysis of the current market and estimations through 2020-2030 that assists in identifying the prevailing market opportunities to capitalize on

• The study comprises a deep dive analysis of the Beta-lactam and Beta-lactamase Inhibitor market trend including the current and future trends for depicting the prevalent investment pockets in the market

• The information related to key drivers, restraints and opportunities and their impact on the Beta-lactam and Beta-Lactamase Inhibitor market is provided in the report.

• The market share of the players in the global Beta-lactam and Beta-lactamase Inhibitor market along with their competitive analysis.

• Value chain analysis in the market study provides a clear picture of the stakeholders’ roles

Key Market Segments

By Type                   

• Individual Beta-lactam Antibiotics                               

  • Penicillins            

    • Natural Penicillins        

    • Aminopenicillins        

    • Extended-Spectrum Penicillins        

  • Cephalosporins            

    • First-Generation        

    • Second-Generation        

    • Third-Generation        

    • Fourth-Generation        

    • Fifth-Generation        

  • Carbapenems            

    • Doripenem        

    • Ertapenem        

    • Imipenem        

    • Meropenem        

  • Monobactams            

• Beta-lactam/Beta-lactamase Inhibitor Combinations                

  • Penicillin Combinations            

    • Amoxicillin-clavulanate        

    • Ampicillin-sulbactam        

    • Piperacillin-tazobactam        

    • Ticarcillin-clavulanate        

  • Cephalosporin Combinations            

    • Ceftazidime-avibactam        

    • Cefepime-tazobactam        

  • Carbapenem Combinations            

    • Meropenem-vaborbactam        

    • Imipenem-relebactam        

  • Others            

By Route of Administration                    

• Oral Administration                

  • Capsules            

  • Tablets            

• Parenteral Administration                

  • Intramuscular Injection (IM)            

  • Intravenous Infusion/Injection (IV)            

• Other Routes                

By Patient Type                    

• Adult Patients                

  • Young Adults (18–40 years)            

  • Middle-Aged Adults (41–64 years)            

  • Senior Adults (≥ 65 years)            

• Pediatric Patients                

  • Adolescents (12–17 years)            

  • Children (2–11 years)            

  • Infants (1 month–1 year)            

  • Neonates (≤ 1 month)            

By Application/Indication (Disease Level)                    

• Gynecological Infections                

  • Pelvic Inflammatory Disease (PID)            

  • Bacterial Vaginosis (if treated with β-lactam)            

  • Other Female-Reproductive-Tract Infections            

• Intrabdominal Infections                

  • Uncomplicated Intra-Abdominal Infection            

• Intraoperative Prophylaxis                

• Respiratory Infections                

  • Complicated Intra-Abdominal Infection            

  • Nosocomial Pneumonia            

    • Hospital-Acquired Pneumonia (HAP)        

    • Ventilator-Associated Pneumonia (VAP)        

    • Other Nosocomial Pneumonia        

• Skin and Soft Tissue Infections (SSTI)                

  • Cellulitis            

  • Erysipelas            

  • Impetigo            

  • Other SSTIs            

• Urinary Tract Infections (UTI)                

  • Acute Uncomplicated UTI            

  • Chronic/Recurrent UTI            

  • Complicated UTI            

• Bloodstream Infections (BSI)                

• Other Infections                

  • Meningitis            

  • Osteomyelitis            

  • Endocarditis            

  • Other Rare/Off-Label Uses            

By End User (Healthcare Setting)                    

• Academic Institutions                

• Clinics                

• Hospitals                

• Research Laboratories

By Geography

• North America

  • Canada

  • U.S.

  • Mexico

• Europe

  • Germany

  • France

  • Spain

  • Italy

  • UK

  • Rest of Europe

• Asia-Pacific

  • Japan

  • India

  • China

  • South Korea

  • Indonesia

  • Thailand

  • Vietnam

  • Taiwan

  • Rest of Asia-Pacific

• RoW

  • Saudi Arabia

  • Brazil

  • Remaining Countries

Key Players:

• Alkem Laboratories Ltd.

• Aurobindo Pharma

• Cipla Inc.

• Dr. Reddy’s Laboratories Ltd.

• GlaxoSmithKline PLC

• Hikma Pharmaceuticals PLC

• Lupin Ltd.

• Meiji Holdings Co. Ltd.

• Merck & Co. Inc.

• Pfizer Inc.

• Sandoz International GmbH (Novartis)

• Shionogi & Co., Ltd.

• Sun Pharmaceutical Industries Ltd.

• Taj Pharmaceuticals Ltd.

• Teva Pharmaceutical Industries Ltd.

• Torrent Pharmaceuticals Ltd.

• Viatris (formerly Mylan N.V.)

• Zeelab Laboratories Ltd.

• Zentiva Group B.V.

• Zydus Lifesciences Limited (Cadila Healthcare)

REPORT SCOPE AND SEGMENTATION: